Objective:To systematically evaluate the clinical efficacy of Yishen Huashi granule combined with ACEI/ARB in the treatment of diabetic kidney disease(DKD).Methods:Seven medical databases including PubMed,Embase,The Cochrane Li-brary,CNKI,CBM,VIP and Wan Fang data,were retrieved from the database until November 20,2023.Standard randomized con-trolled trial(RCTS)of Yishen Huashi Granule for the treatment of DKD was screened according to the pre-determined admission cri-teria,and relevant data were extracted.Then,we used Cochrane bias risk assessment tool to evaluate the quality of the included liter-ature,and Revman5.3 software were used for bias assessment and meta-analysis.Ultimately,a total of 13 articles and 1049 cases were involved,including 530 in the experimental group and 519 in the control group.Results:The results showed that Yishen Huashi Granule combined with ACEI/ARB could improve the overall effective rate of DKD[RR1.24,(95%CI:1.17,1.33),P<0.01],and reduce the urinary albumin excretion rate(UAER)[MD=-23.29(95%CI:-26.93,-19.65),P<0.01],24 h-UTP[MD=-0.04(95%CI:-0.06,-0.01),P<0.01],Scr[MD=-25.60(95%CI:-33.13,-18.07),P<0.01],blood urea nitrogen(BUN)[MD=-2.28(95%CI:-2.49,-2.07),P<0.01],etc.And at the same time,it can reduce fasting blood glucose(FBG)MD=-0.58(95%CI:-1.00,-0.17),P<0.01]and alleviate adverse reactions.Conclusion:The existing evidence shows that Yishen Huashi Granule combined with ACEI/ARB has better efficacy and safety than ACEI/ARB alone in treating DKD pa-tients,which can give full renal protection of diabetic patients.However,in view of the low quality of included study,the conclusion still needs to be verified by a larger sample of high quality and double-blind RCT.
NETL
NSTL
万方数据
